C. Rieger

1.6k total citations · 1 hit paper
21 papers, 918 citations indexed

About

C. Rieger is a scholar working on Epidemiology, Infectious Diseases and Oncology. According to data from OpenAlex, C. Rieger has authored 21 papers receiving a total of 918 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 8 papers in Infectious Diseases and 4 papers in Oncology. Recurrent topics in C. Rieger's work include Antifungal resistance and susceptibility (7 papers), Fungal Infections and Studies (6 papers) and Hematopoietic Stem Cell Transplantation (3 papers). C. Rieger is often cited by papers focused on Antifungal resistance and susceptibility (7 papers), Fungal Infections and Studies (6 papers) and Hematopoietic Stem Cell Transplantation (3 papers). C. Rieger collaborates with scholars based in Germany, Australia and France. C. Rieger's co-authors include Markus Ruhnke, Claus Peter Heußel, Oliver A. Cornely, Andrew J. Ullmann, Helmut Ostermann, Dietmar Reichert, Heinz A. Horst, Eduardo Olavarría, Raoul Herbrecht and Stefan W. Krause and has published in prestigious journals such as Clinical Infectious Diseases, Annals of Oncology and Intensive Care Medicine.

In The Last Decade

C. Rieger

21 papers receiving 892 citations

Hit Papers

Liposomal Amphotericin B as Initial Therapy for Invasive ... 2007 2026 2013 2019 2007 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Rieger Germany 13 585 563 189 105 94 21 918
R. Adams United States 9 520 0.9× 488 0.9× 271 1.4× 129 1.2× 135 1.4× 12 833
Wellington Morais de Azevedo Brazil 6 849 1.5× 799 1.4× 247 1.3× 97 0.9× 98 1.0× 10 1.0k
Michelle K. Yong Australia 14 282 0.5× 487 0.9× 145 0.8× 30 0.3× 59 0.6× 51 766
Angelo Cazzadori Italy 15 337 0.6× 352 0.6× 54 0.3× 145 1.4× 16 0.2× 43 753
Rachel Miller United States 16 510 0.9× 694 1.2× 80 0.4× 49 0.5× 8 0.1× 49 1.1k
Hongwei Fan China 13 670 1.1× 155 0.3× 47 0.2× 50 0.5× 46 0.5× 41 913
J Prignot Belgium 15 342 0.6× 307 0.5× 55 0.3× 178 1.7× 21 0.2× 53 966
Douglas K. Hawley United States 6 164 0.3× 325 0.6× 741 3.9× 180 1.7× 78 0.8× 8 984
José Medina‐Pestana Brazil 15 259 0.4× 328 0.6× 113 0.6× 63 0.6× 19 0.2× 124 998
Jacques Gilquin France 13 447 0.8× 315 0.6× 50 0.3× 16 0.2× 29 0.3× 33 963

Countries citing papers authored by C. Rieger

Since Specialization
Citations

This map shows the geographic impact of C. Rieger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Rieger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Rieger more than expected).

Fields of papers citing papers by C. Rieger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Rieger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Rieger. The network helps show where C. Rieger may publish in the future.

Co-authorship network of co-authors of C. Rieger

This figure shows the co-authorship network connecting the top 25 collaborators of C. Rieger. A scholar is included among the top collaborators of C. Rieger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Rieger. C. Rieger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
3.
Lehners, Nicola, Michael Brodhun, Katharina Boden, et al.. (2016). Influenza virus infections in patients with malignancies –– characteristics and outcome of the season 2014/15. A survey conducted by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). European Journal of Clinical Microbiology & Infectious Diseases. 36(3). 565–573. 28 indexed citations
4.
Fritsch, Susanne, Dušan Prevalšek, Nicole Engel, et al.. (2015). Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplantation. 50(5). 679–684. 16 indexed citations
5.
Tischer, Johanna, Nicole Engel, Susanne Fritsch, et al.. (2014). Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplantation. 49(7). 895–901. 32 indexed citations
6.
Rieger, C., et al.. (2014). What’s new in diagnosis and antimicrobial therapy of febrile neutropenic patients with lung infiltrates?. Intensive Care Medicine. 40(10). 1549–1552. 7 indexed citations
8.
Fiegl, Michael, Michael Unterhalt, Wolfgang Kern, et al.. (2013). Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG. Leukemia. 28(5). 1001–1007. 22 indexed citations
9.
Rieger, C., Oliver A. Cornely, Torsten Hoppe‐Tichy, et al.. (2012). Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. Mycoses. 55(6). 514–520. 20 indexed citations
10.
Rieger, C., et al.. (2009). Infectious complications after allogeneic stem cell transplantation: incidence in matched‐related and matched‐unrelated transplant settings. Transplant Infectious Disease. 11(3). 220–226. 13 indexed citations
11.
Cornely, Oliver A., Johan Maertens, Mark Bresnik, et al.. (2007). Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases. 44(10). 1289–1297. 486 indexed citations breakdown →
12.
Rieger, C., et al.. (2007). Liposomales Amphotericin B bei schweren systemischen Mykosen. DMW - Deutsche Medizinische Wochenschrift. 132(40). 2062–2066. 4 indexed citations
13.
Rieger, C., et al.. (2007). Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. European Journal of Clinical Microbiology & Infectious Diseases. 26(11). 843–845. 20 indexed citations
14.
Rieger, C., Peter Herzog, Roger Eibel, Michael Fiegl, & Helmut Ostermann. (2007). Pulmonary MRI—a new approach for the evaluation of febrile neutropenic patients with malignancies. Supportive Care in Cancer. 16(6). 599–606. 38 indexed citations
15.
Teig, Norbert, et al.. (2006). Prospective Study of Fever After Bronchoalveolar Lavage in Children. Klinische Pädiatrie. 218(2). 74–78. 4 indexed citations
16.
Eibel, Roger, Peter Herzog, Olaf Dietrich, et al.. (2006). Nachweis von pneumonischen Infiltraten mit der MRT. Der Radiologe. 46(4). 267–274. 7 indexed citations
17.
Rieger, C., Michael Fiegl, Johanna Tischer, Helmut Ostermann, & Xaver Schiel. (2004). Incidence and severity of ifosfamide-induced encephalopathy. Anti-Cancer Drugs. 15(4). 347–350. 40 indexed citations
18.
Schoepf, U. Joseph, Manuel Keßler, C. Rieger, et al.. (2001). Diagnostik der Lungenembolie mit der Mehrschicht-Spiral-CT. Der Radiologe. 41(3). 248–255. 4 indexed citations
19.
Rieger, C., et al.. (1994). [Acute oral acetic acid poisoning--case report].. PubMed. 19(3). 80–2. 8 indexed citations
20.
Rieger, C., et al.. (1987). EXPERIMENTAL THROMBUS FORMATION AND HAEMOSTASIS OF DIFFERENT LOW MOLECULAR WEIGHT HEPARINS AND DOSAGES. Thrombosis and Haemostasis. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026